With the new administration's pledge of transparency and whistleblower protection, this year whistleblowers finally seem ready to come clean about the biggest medical scandal. We need to find influential media hosts to provide a platform.
Transcript with citations
The NIH funded a study to evaluate a terrifying vaccine warning raised by the WHO and Dr. Fauci's agency. The results were withheld so I filed this FOIA request naming researchers I confirmed have access.1 The NIH replied they cannot compel them to release their findings despite taxpayer funding. But, the Deputy Chief is trying to help me, like the CDC did last year.
To drum up public support, I wrote three basic questions about the vaccine. If we get media hosts to ask health experts, the audience will be stunned. We just need someone influential to ask the questions, so everybody can see this really is bigger than the Epstein files.
First, exposing vaccine coverups is personal for me because I endure a constant ring in this ear as a result. Right after severe COVID, I was forced to get the mRNA vaccine to work. The experts censored the truth about natural immunity so my recent infection didn't exempt me from the mandate. Hours after having to obey them and reject real science, I had an extreme inflammatory reaction. It left physically verified permanent damage, such as my inner ear, documented in VAERS, which doctors blamed on getting the jab while still recovering.
Now gaslit fanatics insist those mandates never existed, accuse us of fabricating our injuries, and still demand those experts have legal authority over our bodies for the next pandemic. I believe this study is the key to prevent a repeat.
We've engaged the involved scientists and officials to verify I’m presenting only uncontested facts that are a matter of public record.
For background, 1960s vaccines, like polio, were typically made with monkeys, and manufacturers admitted it was impossible to remove the innumerable monkey viruses in the vaccines.2 Some, like SV40, were harmless to monkeys but feared to cause cancer in the hundreds of millions infected by the vaccine.
New York University scientists sought a better solution for hepatitis by surgically connecting patients to various primates to test immune compatibility.3 They found chimpanzee exchange transfusion most effective.
To scale this, the New York Blood Center, NYBC, a major plasma supplier for pharmaceutical companies, wrote: “The use of chimpanzee plasma as an alternate source for Hepatitis-B Immunoglobulin is under consideration…. It could represent a logical source for protective antibody for human use.”3 They noted that mass-production from human plasma was impractical, but chimpanzees provided "large volumes of hyperimmune plasma by plasmapheresis".
Plasmapheresis machines separate plasma from blood and return the rest to the donor. These machines notoriously spread HIV because each new donor is exposed to residual blood from previous donors. They were used to create plasma pools from hundreds of donors—meaning if even one had HIV, the entire pool was infected.
A striking correlation the global scientific community recognizes, but never mentions, is that, as shown in this actual photo of the era, the world’s earliest lab-confirmed HIV-positive being is one of the chimpanzees connected to the plasmapheresis machines repeatedly between 1966 and 1969.4 Chimpanzee #178, “Marilyn,” infected since 1958, was one of only three chimps worldwide that carried a viral strain identified as a likely ancestor to the HIV-1B that emerged in New York and triggered the global pandemic.5–7 The world’s first documented sustained community spread was among New York heroin users.8
NYBC not only injected chimps and heroin users with each others’ blood to test compatibility and connected them to plasmapheresis machines,9 they also used these machines to collect plasma pools sold to pharmaceutical companies, notably for Factor VIII, a hemophilia treatment.10 NYBC also used chimpanzees to develop Factor VIII.
At the time, scientists assumed that, unlike monkeys, chimpanzees could not carry a virus harmless to them but deadly to humans. NYBC argued chimps and humans were biologically identical, stating, “immunologic data provide little basis for separation of these species.”11
In 1972, scientists at the CDC and Dr. Fauci’s agency also confirmed that human and chimpanzee immune systems were identical.12 They, along with senior FDA officials—including one who left to work for Merck—wrote: “The chimpanzee model for hepatitis B has made possible the development of vaccines.”13 That year, the first of several patents for vaccines made from chimp antigens described them as the “practical” solution for affordable mass production14–17, while antibodies were recommended for pregnant women as a “transplacental transfusion” to protect fetuses when the mother was already infected, mostly in endemic regions like Africa.7,10
The FDA and WHO developed reference vaccines from chimpanzee blood18, while the CDC published guidelines for purifying chimpanzee antigens.19
The WHO confirmed chimpanzees produced antigens and antibodies that were “indistinguishable” from humans'.20 The WHO also arranged technology transfers to China and beyond.21 The 1974 WHO Symposium focused on securing chimps for global production.22 Since chimps were considered a proxy to humans, safety testing involved watching for adverse reactions in chimps given the vaccine.23
To meet demand, NYBC acquired private African islands to expand an operation that had supplied chimp blood since the early 1900s.24 It was raw injected into Africans for malaria research25,26, also funded by the agency Fauci would later lead.27,28
Like mRNA today, the use of chimp blood to make vaccines was no secret. It was considered so safe and interchangeable that 1970s patients were routinely transfused with raw chimp blood, such as during surgery where it was used to prime medical equipment.29,30
In 1976, NYBC and Merck tested three candidate vaccines. NYBC’s version explicitly stated it was made from chimpanzee plasma but was controversial for using less purification to cut costs.31,32
Merck produced two versions: the version tested on staff and hospital patients used clear wording to unequivocally state it was made from human plasma.31 It received FDA approval, and was sold as Heptavax-B. However, Merck described their other version, given to gay men, this way. Quote:
Infected human plasma contains Hepatitis-B antigen… The vaccine is prepared from antigen... Adult human subjects given Lot 751 human hepatitis B vaccine.33
Merck’s awkward, species-ambiguous wording used “human” three times but technically, only said the vaccine was for humans, not made from human plasma. This lower cost species-ambiguous version was never FDA-approved and was sold overseas as H-B-Vax.34 Some claim it was also made from human plasma. But Merck always called it “carrier plasma” without specifying the species. And like NYBC’s patents, Merck’s original patent lists plasmapheresis and names only one species as an antigen source–the chimpanzee.16 Only after testing the vaccine did Merck refile the patent to add the word ‘human’, which was never used in the original.35
The phase 3 trials began in 1978.36 Two months in the trial, the world’s first gay man developed unexplained skin bumps37, now agreed to be caused by, not one virus, but rather simultaneous co-infection with two unrelated, unknown viruses, both found in the chimpanzees used to make the vaccine: HIV and Kaposi’s Sarcoma Herpes Virus.38,39
However, only HIV correlates with sexual activity. Kaposi's Sarcoma Herpes Virus does not.40 AIDS with Kaposi's Sarcoma, that is the simultaneous infection with both chimpanzee viruses, was largely limited to gay men at vaccine trial sites infected during the vaccine trial.41
The men were in New York, but NYBC deflected claims of a link, writing: “None of the patients with Kaposi's Sarcoma were participants in the Hepatitis B vaccine trial. Therefore, we do not think that the epidemic is caused by or related to the vaccine.”42
Incredibly, NYBC has told us they never disclosed whether those early cases were among the hundreds vaccinated before the phase 3 trial. However, ten months into the trial, NYBC’s lead scientist, Wolf Szmuness, reported a dozen flare-ups, this time in phase 3 participants who had received Merck’s species-ambiguous version—almost all were in men he’d vaccinated, not the placebo group.43 Participants given Merck's human plasma version were fine. Szmuness admitted fearing jail if it proved serious.
By the trial’s end, Szmuness was jailed in Brazil for “deranged behavior” and soon died—officially from lung cancer that spread to his brain.44 Unknown at the time, nearly half the participants who received Merck’s species-ambiguous vaccine were already HIV-positive.45 Prestigious journals like the Lancet were reporting fears that Szmuness’s trial had introduced a novel pathogen.46 His Wikipedia page dismisses any AIDS link for “lacking a mechanism,” ignoring that Szmuness himself suspected an unknown virus in the blood plasma used for the vaccine.
Now to the questions. Show the experts the official November 15, 1982 WHO Symposium Proceedings, available on archive.org.10
It includes Dr. Szmuness’s obituary. And on page 13 NYBC refers to their chimpanzee-plasma version, which they had proposed for the 1978 phase 3 trials presumably after they’d tested it on some of the 13,000 gay men they’d recruited with these flyers. They confirm unequivocally that they did use it in some unspecified clinical trials.
They admit they were vaccinating people with antigens from chimpanzee blood plasma. That is stated in black and white.
Question 1: Did AIDS appear in any who got chimpanzee based vaccines, or immunoglobulin, or cross circulation or blood transfusion?
Watch—you’ll never get a straight answer. In the 1970s, scientists touted chimpanzees as a safer alternative to monkeys, yet ever since AIDS was linked to a chimpanzee virus, the Global Health Community pretends chimpanzee-based products never existed—despite hundreds of documents proving otherwise.
The WHO transcript reveals this gathering of 1,000 global health leaders opened with “much controversy” over chimpanzee-based vaccines, used in “many countries” and widely suspected of causing a new syndrome emerging wherever they were administered. Even those remote, isolated Chinese villages would soon be decimated.
Similar symptoms followed the use of Factor VIII, that hemophilia treatment developed with chimpanzees and sourced from NYBC’s plasmapheresis reservoir. Notably, until that year, no one had AIDS from blood transfusion. Scientists expected the blood supply to have been contaminated first.47 But it was not, suggesting these plasma-derived products made using the chimpanzee model may have been the original source.
On page 135, Dr. Purcell, co-inventor of the chimpanzee model at Fauci’s agency who, 10 years earlier, praised the biocompatibility of chimpanzee and human blood, agreed an alternative was needed, acknowledging that the newly named AIDS could indeed be caused by a virus in the plasma used to make the vaccine, just as everyone suspected.
Within months, scientists isolated the causal virus in blood.48 But, that senior FDA official and former FDA official at Merck who helped develop the chimpanzee model, released this public defense of the vaccine and “lifesaving” Factor VIII, noting each lot had first been tested on chimpanzees, and the chimpanzees showed no sign of AIDS.49 The FDA argued AIDS was likely not transmissible through blood, but rather caused by herpes or gay party drugs. They identified three groups affected: gay men, heroin users, and recent Haitian migrants, the majority of whom were in a single Florida hospital.50 AIDS in Florida’s Haitian migrants was such a “complete mystery,” unraveling it was seen as key to cracking the enigma.51,52 New York, like other major Haitian migrant centers in Canada and France, found no elevated risk in Haitians.53 Only in Florida, AIDS rates were alarmingly high, particularly among a rural community of heterosexual Haitian farmworkers with no known risk factors.54
The claim that HIV entered the U.S. via Haiti is based entirely on five of those recent Haitian migrants in Florida carrying an ancestral HIV strain.55 However, no one has acknowledged that Florida uniquely mandated hepatitis testing for Haitian migrants upon entry, presumably for vaccination.56
Thus, when the FDA assured the public that AIDS couldn’t come from Factor VIII or the vaccine—both made with NYBC blood and tested on chimpanzees connected to plasmapheresis machines—they ignored that these products were the only common link between hemophiliacs, New York heroin users, gay men, and Haitian migrants in Florida.
Nearly 20 years later, litigation revealed the FDA knew some products were transmitting HIV, but, incredibly, they succeeded in keeping it out of the public eye.57 This allowed the contaminated inventory to be sold overseas, saving Big Pharma the cost of writing it off. We seek to establish if, somehow, they also succeeded in keeping out of the public eye the role of plasma-derived vaccines and the chimpanzees used to make them.
Question 2: If you also cannot find mention of the use of chimpanzee blood after that 1982 Symposium, does that suggest a cover up?
For two years, I've asked everyone to fact-check. If no cover-up exists, show me where medical use of chimpanzee blood was ever mentioned again. How was there no follow-up with recipients after the discovery AIDS was indeed caused by a virus in chimpanzee blood? Are we supposed to believe that the entire global health community was panicking over chimpanzee-based products and the next day they forgot they ever existed?
With “enthusiastic support” from South Africa’s apartheid regime, the WHO continued using Merck’s species-ambiguous vaccine on Black rural communities into the 1990s—long after they had expired and plasma-free versions were standard elsewhere.58 This relied on assurances from Dr. Purcell, the Fauci scientist who first warned they might cause AIDS. He later assured the WHO it was a false alarm, and those original lots were safe after all, allegedly based on private communication from Cladd Stevens.59 She ran the NYBC trial with Szmuness. Purcell claimed she had reported outcomes were similar between men who got the vaccine and placebo in the New York trials. However, publicly Stevens only released this average HIV rate of vaccine and placebo combined.45
But I contacted Dr. Stevens and other NYBC scientists, spending hours on calls and emails. Drs. Stevens and Koblin do have the pivotal HIV rate broken down by vaccine and placebo, but have never shared it—not even with colleagues—and will not explain why it’s top-secret.
Our new FOIA requests the data withheld for 40 years to prove if Fauci’s scientist misspoke, resulting in the WHO spreading AIDS when they thought they were combating it.1
The CDC also ran a five-city trial, centered in San Francisco, using the same original H-B-Vax lot as New York.60 They also tested archived blood samples to track when each participant contracted HIV.
As in New York, all blood samples collected before 1977 were HIV-negative.61 They concluded HIV entered the gay community during the phase 2 trials around 1977. A few cases appeared in 1978, Phase 3's first year, and by the end, nearly half the men were infected, mirroring New York.
The CDC and NYBC could have settled accusations by showing the HIV rate in men who received placebo on their charts. Instead, they issued these deceptive word salads giving the illusion of similar rates, while leaving open the possibility they were comparing infections after the trial rather than during the trial.62,63 However, San Francisco health officials dropped three clear hints:
First, they noted HIV rates in the highest risk gay men with STD’s was half that of trial participants who had clean STD histories.64
I reached out to the scientists and got confirmation that hint slash warning was intentional.
Second, they reported AIDS was "quite different" when contracted sexually vs. by injection—noting vaccinated gay men had AIDS indicating injection, not sexual transmission.65 After nobody got that hint, in this unrelated paper, they inexplicably listed HIV status in trial participants atop this vaccine dose chart—showing precisely dose-dependent HIV rates.66
I got the hint and filed this CDC FOIA request.67 The former Deputy Director responded that, somehow, I’m the first person to ask why half the men given the vaccine contracted HIV during the trial while the placebo group was largely spared. He claims nobody asked questions and he discarded the trial data without investigating.
Question 3: How do you explain San Francisco's dose-dependent HIV rates? If New York’s rates are released and show the same pattern, will you admit this supports health leaders' original theory of vaccine-transmission?
Scientists had been injecting Africans with raw chimpanzee blood since the early 1900s before it became mainstream in the 1970s.25 While a few HIV strains predate the AIDS pandemic, the 1980s saw a global explosion of never-before-seen strains, generally recognized as evidence of multiple chimp-to-human transmissions.68
Scientists now claim every one of those transmissions resulted from chimp blood in African hunters' wounds, yet their initial suspicions about their own chimp-blood injections were based on striking correlations.
In 1986, WHO scientists noted AIDS' explosive African spread was recent: Note few HIV cases in children over 1, but high rates in newborns—indicating mass introduction within the last 12 months.69 New mothers had high infection rates—their husbands did not. Half of infected newborns had uninfected mothers, ruling out sexual transmission. This correlates with the arrival of leftover hepatitis vaccines and/or HBIG for pregnant women and newborns. And, incidentally 16 of 17 lots being used did test positive for HIV antibodies, but, rather than discarding them they argued "it seems very likely that the manufacturing process inactivates HIV and there is no need for alarm”.70 They kept using them.
As mentioned earlier, in the U.S., the correlation is striking—NYBC harvested blood from both Marilyn and New York heroin users using plasmapheresis to test cross-species compatibility in 19694,9,71, the same year Fauci’s Proximal Origins authors pinpointed HIV’s U.S. entry.55
Note this key claim in their paper: that HIV entered the U.S. via Haitians returning from Africa. This idea originated in this video from Fauci. He proposed it the same year HIV was identified and Marilyn tested positive, providing strong support for his agency’s initial theory blaming their own chimpanzee model:
Let me tell you another fact. In the late '60s and early '70s, thousands, not a few, but thousands, of Haitians came to Zaire, particularly in Kinshasa, the capital, to work as technical advisers for the Zairian government. After several years there, because of the nationalization of much of the industry, they were essentially kicked out of Zaire and came back to Haiti, to the United States, and to Canada.
The timeline proves Fauci’s revision is impossible—that nationalization program was announced in 1973, at least three years after their own analysis dated HIV’s U.S. entry. The Proximal Origins authors grossly misquoted this study, claiming it provided evidence supporting their conflicted timeline. In reality, the study stated no such evidence exists, as not one Haitian returning from Africa had AIDS, concluding Fauci’s revision must be viewed with skepticism.72
The first Haitians diagnosed with AIDS were the recent Florida migrants. International scientists reviewed historical records in Haiti and the US and insist there was no AIDS in Haiti nor in Haitian migrants before the New York outbreak in gay men73,74—several years after HIV was already circulating in New York heroin users. Yet, after Fauci’s video, the strain that originated in New York heroin users was labeled the “Haitian strain,” and every discussion of AIDS origins included his impossible returning Haitian narrative.
An internal WHO report concluded 10 million people were being infected every year through medical injections, causing a baby to die every 20 seconds.75 Well-intentioned scientists struggled in vain to stop it.76 They’ve privately admitted to us they failed because they only considered dirty needles, without taking into account contaminated pharmaceuticals. They thought vaccines had been ruled out by Fauci’s agency's claim of similar AIDS rates in placebo recipients during the trial. Also Fauci’s claim of HIV’s U.S. arrival via returning Haitians was considered settled science. They now admit we’ve provided the “best account of probable HIV origins,” though we’re merely presenting the vaccine inventor’s original theory when he observed symptoms in a dozen trial participants.
I’ve asked scientists why they dismiss as coincidence that blood from the earliest known HIV-positive being was used to treat Hepatitis in the group with the first documented community spread.
This private reply from an involved NYBC scientist called HIV vaccine transmission "plausible, albeit unlikely". As you can see, scientists recognize the incredible timing. But they believe it would have taken decades for HIV-1B to evolve from the chimpanzee strain.
I point out that 1960s Hepatitis treatments were not just injections–patients were surgically connected to batteries of chimps, allowing mixed raw blood to flow back and forth while the chimp’s immune system attacked the virus.3 I ask if that’s effectively serial passaging in gain-of-function—constant transmission to accelerate viral evolution. I hope media hosts ask the experts on camera so you too can see the look on their faces.
I founded FactMission as a nonprofit to pioneer this new approach to research—not to prove or disprove conspiracy theories, but to isolate core facts that all sides agree are accurate. This combats "firehose propaganda"—the tactic of flooding discourse with wild theories so people don’t know what to believe.
This happened with AIDS. Initially, the explanation was simple: chimpanzee blood products transmitted chimpanzee viruses. But right after Dr. Fauci took over, rational discussion was derailed by these leaks from a so-called CIA watchdog, claiming HIV was an engineered bioweapon intentionally added to Hepatitis vaccines.77
I don’t know enough to have an opinion on HIV being lab-manipulated. But even sticking to the mainstream narrative that it was natural chimp blood transmission, it's reasonable there was some introduction from early 20th century injection of raw chimp-blood for malaria, and from the 1958 Congo polio vaccine, and maybe from cut hunters. But consider the groups with explosive 1980s AIDS: New York heroin users, US and European gay men, impoverished Haitian migrants, conservative South African villages, and rural Chinese farmers. None live near chimpanzees, they have wildly different sexual habits, and the only thing they have in common is high Hepatitis rates targeted by the 1970s campaigns local officials initially suspected.
Unlike covid, AIDS is easy to solve. We don't need to debate this. NIH just needs to release the New York data. Either vaccine-placebo rates were similar, like Fauci’s scientist assured the WHO, and I'll admit I'm wrong. Or there’s a discrepancy like in San Francisco. If so, they deceived the WHO and sacrificed the African continent to cover up vaccine harms and to protect their reputations and pharma profits.
Note they're the ones hiding the vaccine placebo breakdown they claimed would settle this. Please, let’s get the media to cover this so there's pressure to release it.
Thank you.
References
1. NIH Freedom of Information Request 63388. Published online January 31, 2025. https://drive.google.com/file/d/1x0YYPKstsiii3dZpzxeWv5k1tIQP3BgS/view?usp=sharing
2. Curtis T. The Origin Of Aids: A Startling New Theory Attempts To Answer The Question “Was It An Act Of God Or An Act Of Man?” Accessed January 27, 2025. https://documents.uow.edu.au/~bmartin/dissent/documents/AIDS/Curtis92.html
3. Goldsmith EL, Moor-Jankowski J. Medical Primatology 1970: Selected Papers from the 2. Conference on Experimental Medicine and Surgery in Primates : New York, N.Y., September 1969.; 1971. https://openlibrary.org/works/OL11211497W/Medical_primatology_1970?edition=key%3A/books/OL14754625M
4. Gilden R, Arthur L, Robey WG, Kelliher J, Graham C, Fischinger P. Htlv-III Antibody In A Breeding Chimpanzee Not Experimentally Exposed To The Virus. The Lancet. 1986;327(8482):678-679. doi:10.1016/S0140-6736(86)91749-6
5. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee. 1999;397. doi:10.1038/17130
6. Greenwood EJD, Schmidt F, Heeney JL. Simian Immunodeficiency Virus Infection of Chimpanzees (Pan troglodytes). In: Natural Hosts of SIV. Elsevier; 2014:85-101. doi:10.1016/B978-0-12-404734-1.00005-X
7. Goldsmith EI, Moor-Jankowski J. Medical Primatology 1972: Selected Papers - Part 3. S. Karger; 1972. https://www.google.com/books/edition/Medical_Primatology_1972/d6NqAAAAMAAJ?hl=en&kptab=publisherseries
8. Jarlais DCD, Friedman SR, Novick DM, et al. HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987.
9. Prince AM, Szmuness W, Woods KR, Grady GF. Antibody against Serum-Hepatitis Antigen. N Engl J Med. 1971;285(17):933-938. doi:10.1056/NEJM197110212851702
10. WHO/IABS Symposium on Viral Hepatitis (2nd : 1982 : Athens G. Second WHO/IABS Symposium on Viral Hepatitis : Standardization in Immunoprophylaxis of Infections by Hepatitis Viruses : Proceedings of a Symposium. Basel ; New York : S. Karger; 1983. Accessed July 8, 2024. http://archive.org/details/secondwhoiabssym0000whoi
11. Trends in Bioassay Methodology: In Vivo, in Vitro and Mathematical Approaches : Proceedings of the Symposium on Trends in Bioassay Methodology: In Vivo, in Vitro and Mathematical Approaches, February 18-20, 1981, Pan American Health Organization Building, Washington, D.C. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1981. https://babel.hathitrust.org/cgi/pt?id=umn.31951d003693889&seq=9
12. Maynard JE, Berquist KR, Krushak DH, Purcell RH. Experimental Infection of Chimpanzees with the Virus of Hepatitis B. Nature. 1972;237(5357):514-515. doi:10.1038/237514a0
13. Tabor E, Purcell RH, Gerety RJ. Primate Animal Models and Titered Inocula for the Study of Human Hepatitis A, Hepatitis B, and Non-A, Non-B Hepatitis. J Med Primatol. 1983;12(6):305-318. doi:10.1111/j.1600-0684.1983.tb00095.x
14. Prince AM, Vnek J, Neurath RA, Trepo C. Vaccine manufacture for active immunization containing hepatitis B surface antigen and associated antigen. Published online October 3, 1978. Accessed July 5, 2024. https://patents.google.com/patent/US4118478A/en
15. Vnek J, Prince AM. Large scale purification of hepatitis type B antigen using polyethylene glycol (1972 Patent). Published online April 20, 1976. Accessed July 5, 2024. https://patents.google.com/patent/US3951937A/en
16. Bertland AU, Tytell AA, Lampson GP, Buynak E. Method for purifying hepatitis B antigen. Published online April 12, 1977. Accessed July 13, 2024. https://patents.google.com/patent/US4017360A/en
17. Prince AM, Vnek J, Neurath RA, Trepo C. Vaccine for active immunization containing hepatitis B surface antigen and associated antigen (1975). Published online October 3, 1978. Accessed July 8, 2024. https://patents.google.com/patent/US4118479A/en
18. Tabor E, Howard CR, Skelly J, et al. Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles. J Med Virol. 1982;10(1):65-74. doi:10.1002/jmv.1890100109
19. Fields HA, Bradley DW, Davis CL, Maynard JE. Purification and partial characterization of hepatitis e antigen (HBeAg). Infect Immun. 1978;20(3):792-803. doi:10.1128/iai.20.3.792-803.1978
20. Zuckerman AJ, Thornton A, Howard CR, Tsiquaye KN, Jones DM, Brambell MR. Hepatitis B Outbreak Among Chimpanzees At The London Zoo. The Lancet. 1978;312(8091):652-654. doi:10.1016/S0140-6736(78)92761-7
21. Muraskin WA. The War Against Hepatitis B: A History of the International Task Force on Hepatitis B Immunization. University of Pennsylvania Press; 1995.
22. Regamey RH, Hennessen W, Perkins FT. International Symposium on Viral Hepatitis: Proceedings of the 44th Symposium Organized by the International Association of Biological Standardization and Held at the Congress Hall, Via Corridoni, Milan, Italy, 16-19 December 1974. S. Karger; 1975.
23. Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR. Development and chimpanzee testing of a vaccine against human hepatitis B. Proc Soc Exp Biol Med Soc Exp Biol Med N Y N. 1976;151(4):694-700. doi:10.3181/00379727-151-39288
24. Prince AM. The Poetry of Life: In Science In Africa and Manzee. Xlibris Corporation; 2010.
25. Kolata G. Theory Links AIDS to Malaria Experiments. The New York Times. https://www.nytimes.com/1991/11/28/us/theory-links-aids-to-malaria-experiments.html. November 28, 1991. Accessed January 13, 2025.
26. Gilks C. AIDS, monkeys and malaria. Nature. 1991;354(6351):262-262. doi:10.1038/354262a0
27. Rudzinska MA, Trager W, Bray RS. Pinocytotic uptake and the digestion of hemoglobin in malaria parasites. J Protozool. 1965;12(4):563-576. doi:10.1111/j.1550-7408.1965.tb03256.x
28. Bray RS. Studies on Malaria in Chimpanzees: II. Plasmodium vivax. Am J Trop Med Hyg. 1957;6(3):514-520. doi:10.4269/ajtmh.1957.6.514
29. Wiener AS, Moor-Jankowski J. Blood Groups of Apes and Monkeys-Their Practical Implications for Experimental Medicine. Ann N Y Acad Sci. 1969;162(1):37-42. doi:10.1111/j.1749-6632.1969.tb56345.x
30. Goldsmith EI, Moor-Jankowski J. Medical Primatology 1972: Selected Papers - Part 1. S. Karger; 1972. https://openlibrary.org/books/OL5475007M/Medical_primatology_1972
31. Vyas GN, Cohen SN, Schmid R. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis, and Prevention : Proceedings of the Second Symposium on Viral Hepatitis, University of California, San Francisco, March 16-19, 1978. Franklin Institute Press; 1978. https://www.google.com/books/edition/Viral_Hepatitis/DGFsAAAAMAAJ
32. Vnek J, Ikram H, Prince AM. Heterogeneity of hepatitis B surface antigen-associated particles isolated from chimpanzee plasma. Infect Immun. 1977;16(1):335-343. doi:10.1128/iai.16.1.335-343.1977
33. Szmuness W, Alter HJ, Maynard JE. Viral Hepatitis: 1981 International Symposium. Franklin Institute Press; 1982. https://books.google.com/books?id=0r9pAAAAMAAJ
34. McLean AA, Hilleman MR, McAleer WJ, Buynak EB. Summary of worldwide clinical experience with H-B-Vax® (B, MSD). J Infect. 1983;7:95-104. doi:10.1016/S0163-4453(83)96879-2
35. McAleer WJ, Wasmuth EH. Method for preparing hepatitis B immune globulin. Published online November 13, 1979. Accessed July 13, 2024. https://patents.google.com/patent/US4174388A/en
36. Szmuness W. Large‐scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols. J Med Virol. 1979;4(4):327-340. doi:10.1002/jmv.1890040411
37. Gottlieb GJ, Ackerman AB. Kaposi’s sarcoma: An extensively disseminated form in young homosexual men. Hum Pathol. 1982;13(10):882-892. doi:10.1016/S0046-8177(82)80047-6
38. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular Genetics of Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol Mol Biol Rev. 2003;67(2):175-212. doi:10.1128/MMBR.67.2.175-212.2003
39. Greensill J, Sheldon JA, Murthy KK, Bessonette JS, Beer BE, Schulz TF. A chimpanzee rhadinovirus sequence related to Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8: increased detection after HIV-1 infection in the absence of disease: AIDS. 2000;14(17):F129-F135. doi:10.1097/00002030-200012010-00001
40. O’Brien TR, Kedes D, Ganem D, et al. Evidence for Concurrent Epidemics of Human Herpesvirus 8 and Human Immunodeficiency Virus Type 1 in US Homosexual Men: Rates, Risk Factors, and Relationship to Kaposi’s Sarcoma. J Infect Dis. 1999;180(4):1010-1017. doi:10.1086/315039
41. Osmond DH. Prevalence of Kaposi Sarcoma–Associated Herpesvirus Infection in Homosexual Men at Beginning of and During the HIV Epidemic. JAMA. 2002;287(2):221. doi:10.1001/jama.287.2.221
42. Poleski MH. Kaposi’s sarcoma and hepatitis B vaccine. Ann Intern Med. 1982;97(5):786-787. doi:10.7326/0003-4819-97-5-786_3
43. Goodfield J, ed. Quest for the Killers. Birkhäuser Boston; 1985. doi:10.1007/978-1-4684-6743-7
44. Wolf Szmuness and the Hepatitis B Vaccine Trial. Accessed July 5, 2024. https://www.webofstories.com/people/baruch.blumberg/30?o=SH
45. Stevens CE, Taylor PE, Zang EA, et al. Human T-Cell Lymphotropic Virus Type Hi Infection in a Cohort of Homosexual Men in New York City. Published online 1986. doi:10.1001/jama.1986.03370160065028
46. Mcdonald M, Hamilton J, Durack D. Hepatitis B Surface Antigen Could Harbour The Infective Agent Of Aids. The Lancet. 1983;322(8355):882-884. doi:10.1016/S0140-6736(83)90871-1
47. Bradley DW, Cook EH, Maynard JE, et al. Experimental infection of chimpanzees with antihemophilic (factor viii) materials: Recovery of virus-like particles associated with non-A, non-B hepatitis. J Med Virol. 1979;3(4):253-269. doi:10.1002/jmv.1890030403
48. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS). Science. 1983;220(4599):868-871. doi:10.1126/science.6189183
49. Gerety RJ. Newly Licensed Hepatitis B Vaccine: Known Safety and Unknown Risks. JAMA. 1983;249(6):745. doi:10.1001/jama.1983.03330300029028
50. Opportunistic Infections and Kaposi’s Sarcoma among Haitians in the United States. Accessed September 29, 2024. https://www.cdc.gov/mmwr/preview/mmwrhtml/00001123.htm
51. Charbonneau J, Tran N. The Paradoxical Situation of Blood Donation in the Haitian-Quebec Community. Can Ethn Stud. 2015;47:67-92. doi:10.1353/ces.2015.0021
52. Carlson RG, Farmer P. AIDS and Accusation: Haiti and the Geography of Blame. Anthropol Q. 1994;67(2):95. doi:10.2307/3317365
53. Altman LK. DEBATE GROWS ON U.S. LISTING OF HAITIANS IN AIDS CATEGORY. The New York Times. https://www.nytimes.com/1983/07/31/us/debate-grows-on-us-listing-of-haitians-in-aids-category.html. July 31, 1983. Accessed March 15, 2025.
54. Castro KG, Lieb S, Jaffe HW, et al. Transmission of HIV in Belle Glade, Florida: Lessons for Other Communities in the United States. Science. 1988;239(4836):193-197. doi:10.1126/science.3336781
55. Gilbert MTP, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci. 2007;104(47):18566-18570. doi:10.1073/pnas.0705329104
56. Malison MD, Kane MA, Johnson JM, Schable CA, Gridley MJ, Polkowski J. A seroprevalence survey of hepatitis B markers among Haitians in a southwest Florida farming community. Am J Public Health. 1985;75(9):1094-1095. doi:10.2105/AJPH.75.9.1094
57. Bogdanich W, Koli E. 2 Paths of Bayer Drug in 80’s: Riskier One Steered Overseas. The New York Times. https://www.nytimes.com/2003/05/22/business/2-paths-of-bayer-drug-in-80-s-riskier-one-steered-overseas.html. May 22, 2003. Accessed July 5, 2024.
58. Schoub BD, Johnson S, McAnerney JM, et al. Integration of hepatitis B vaccination into rural African primary health care programmes. BMJ. 1991;302(6772):313-316. doi:10.1136/bmj.302.6772.313
59. Verme G, Bonino F, Rizzetto M. Viral Hepatitis and Delta Infection: Proceedings of an International Symposium on Viral Hepatitis, June 10-11, 1983, Torino, Italy. A.R. Liss; 1983.
60. Hessol NA, Lifson AR, O’Malley PM, Doll LS, Jaffe HW, Rutherford GW. Prevalence, Incidence, And Progression Of Human Immunodeficiency Virus Infection In Homosexual And Bisexual Men In Hepatitis B Vaccine Trials, 1978–1988. Am J Epidemiol. 1989;130(6):1167-1175. doi:10.1093/oxfordjournals.aje.a115445
61. Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ. 1990;301(6762):1183-1188. doi:10.1136/bmj.301.6762.1183
62. Stevens CE, Taylor PE, Rubinstein P, et al. Safety of the hepatitis B vaccine. N Engl J Med. 1985;312(6):375-376. doi:10.1056/NEJM198502073120613
63. Current Trends Hepatitis B Vaccine: Evidence Confirming Lack of AIDS Transmission. 1984. Accessed July 5, 2024. https://www.cdc.gov/mmwr/preview/mmwrhtml/00000449.htm
64. Rutherford W, Hessol A, Winkelstein W, Moss AR, Chen RT, Thomas PA. Projections of AIDS Morbidity and Mortality in San Francisco. doi:10.1001/jama.1990.03440110063029
65. Bacchetti P, Segal MR, Hessol NA, Jewell NP. Different AIDS incubation periods and their impacts on reconstructing human immunodeficiency virus epidemics and projecting AIDS incidence. Proc Natl Acad Sci U S A. 1993;90(6):2194-2196. doi:10.1073/pnas.90.6.2194
66. Hadler SC, Judson FN, O’Malley PM, et al. Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection. J Infect Dis. 1991;163(3):454-457. doi:10.1093/infdis/163.3.454
67. Andoh R. CDC Freedom of Information Request 24-00408. Accessed January 25, 2025. https://drive.google.com/file/u/1/d/1Xp31mwVmLwgNT4yj6EaqLhRbWDd9pB8k/view?usp=drive_link&usp=embed_facebook
68. Sharp PM, Hahn BH. Origins of HIV and the AIDS Pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841-a006841. doi:10.1101/cshperspect.a006841
69. Quinn TC, Mann JM, Curran JW, Piot P. AIDS in Africa: An Epidemiologic Paradigm. Science. 1986;234(4779):955-963. doi:10.1126/science.3022379
70. Gocke DJ, Raska K, Pollack W, Schwartzer T. HTLV-III antibody in commercial immunoglobulin. Lancet Lond Engl. 1986;1(8471):37-38. doi:10.1016/s0140-6736(86)91914-8
71. Cherubin CE, Hargrove RL, Prince AM. The Serum Hepatitis Related Antigen (SH) In Illicit Drug Users. Am J Epidemiol. 1970;91(5):510-517. doi:10.1093/oxfordjournals.aje.a121161
72. Piot P, Taelman H, Bila Minlangu K, et al. Acquired Immunodeficiency Syndrome In A Heterosexual Population In Zaire. The Lancet. 1984;324(8394):65-69. doi:10.1016/S0140-6736(84)90241-1
73. Pape JW, Liautaud B, Thomas F, et al. Characteristics of the Acquired Immunodeficiency Syndrome (AIDS) in Haiti. N Engl J Med. 1983;309(16):945-950. doi:10.1056/NEJM198310203091603
74. Pape JW, Farmer P, Koenig S, Fitzgerald D, Wright P, Johnson W. The epidemiology of AIDS in Haiti refutes the claims of Gilbert et al. Proc Natl Acad Sci. 2008;105(10). doi:10.1073/pnas.0711141105
75. Writers RH William Carlsen, Chronicle Staff. DEADLY NEEDLES / Fast Track to Global Disaster. SFGATE. October 27, 1998. Accessed October 16, 2024. https://www.sfgate.com/health/article/DEADLY-NEEDLES-Fast-Track-to-Global-Disaster-2982689.php
76. Brewer DD, Brody S, Drucker E, et al. Mounting anomalies in the epidemiology of HIV in Africa: cry the beloved paradigm. Int J STD AIDS. 2003;14(3):144-147. doi:10.1258/095646203762869142
77.Lederer R. Covert Action Number 28. Summer 1987. Accessed July 19, 2024. https://www.cia.gov/readingroom/docs/CIA-RDP90-00845R000100170001-8.pdf
Share this post